COMMUNIQUÉS West-GlobeNewswire

ProMIS Neurosciences Completes Private Placement of Units
23/01/2019
NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ ProMIS ” or the “ Company ”) (TSX: PMN); (OTCQB:ARFXF) is [...]
T2 Biosystems to Participate in Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
23/01/2019
Company to highlight groundbreaking diagnostic innovations impacting antimicrobial resistance and sepsis management LEXINGTON, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the [...]
Sharps Compliance Reports Fiscal 2019 Second Quarter Results
23/01/2019
Second quarter 2019 revenue increased to $12.4 million with gross margin of 32%, net income of $0.8 million and $0.05 earnings per share Mailback business increased 20% for the quarter reflecting strong flu business [...]
Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019
23/01/2019
ORION CORPORATION PRESS RELEASE 23 JANUARY 2019 at 13.30 EET Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019 Orion will publish its Financial Statement Release for 2018 on [...]
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
23/01/2019
Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. ( [...]
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
23/01/2019
Results Confirm Safety Profile and Demonstrate Meaningful Potential Benefits in Mortality, Ventilator-free Days and ICU-free Days CLEVELAND, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced [...]
New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
23/01/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced that new data showing the [...]
Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock
23/01/2019
WARREN, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten [...]
CORRECTION: Aino Health AB (publ): Smart Health Management brought big rewards for Tornio
23/01/2019
This is a correction of the announcement from 08:30 23.01.2019 CET. Reason for the correction: January 23 2019 The municipality of Tornio is a forerunner in the strategic utilization of health management. The work, [...]
Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
23/01/2019
Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Aino Health AB (publ): Smart Health Management brought big rewards for Tornio
23/01/2019
January 23 2019 The municipality of Tornio is a forerunner in the strategic utilization of health management. The work, started ten years ago, has yielded solid results. Anja Huhtanen, HR Manager for Tornio, says that [...]
Saniona reports UPenn to continue cocaine addiction study with NS2359 at higher dose after blinded interim analysis
23/01/2019
PRESS RELEASE January 23, 2019 University of Pennsylvania Treatment Research Center continues investigator-initiated study Decision based on interim analysis of blinded data for first 50 patients Good scientific [...]
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
23/01/2019
SINGAPORE, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
23/01/2019
Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
23/01/2019
OCALA, Fla., Jan. 23, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced [...]
Management Cease Trade Order Update
23/01/2019
HALIFAX, Nova Scotia, Jan. 22, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued [...]
Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22/01/2019
WARREN, N.J., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell [...]
Rexahn Announces Proposed Public Offering of Common Stock and Warrants
22/01/2019
ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its [...]
Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
22/01/2019
BURLINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, [...]

Pages